Venture Funding Deals: Relay Closes Out 2018 With $400m Series C
2018 was a banner year for venture funding, and Relay's December Series C was only the third largest VC round of the year. Other year-end financings include Millendo, Erasca, Aristea and more...
You may also be interested in...
Private Company Edition: VC deals are surging this year for cell and gene therapy firms, according to ARM’s third quarter report. Also, Vivo Capital and the CF Foundation plan to invest nearly $2bn in health care and life science opportunities, and Akeso completes $150m series D.
A Toll-like receptor-9 agonist under development by Sweden’s InDex Pharmaceuticals showed encouraging clinical responses in top-line results in patients with active ulcerative colitis not responding to other agents. Its novel mechanism of action and relatively benign side effect profile makes it a prime candidate to combine with biologic agents.
Merck KGaA and Artios penned a global three-year strategic research collaboration to discover and develop multiple precision oncology drugs. The deal could be worth close to $7bn for four-year-old Artios. AstraZeneca announced a definitive agreement to acquire public rare disease drug developer Alexion for approximately $39bn. This was 2020’s largest M&A. Financing reached $28bn in biopharma, $879m in device, and $2.4bn in diagnostics.